What is Achieve Life Sciences Inc's earnings per share (EPS)?

Achieve Life Sciences Inc (ACHV) reported diluted earnings per share of $-1.25 for fiscal year 2025. This represents a -0.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Achieve Life Sciences Inc Financials

ACHV

Source SEC Filings (10-K/10-Q) Updated Mar 24, 2026 Currency USD FYE March

This page shows Achieve Life Sciences Inc (ACHV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.91x

For every $1 of reported earnings, Achieve Life Sciences Inc generates $0.91 in operating cash flow (-$49.5M OCF vs -$54.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$54.6M

YoY-37.2%

Achieve Life Sciences Inc reported -$54.6M in net income in fiscal year 2025. This represents a decrease of 37.2% from the prior year.

EPS (Diluted)

$-1.25

YoY-0.8%

Achieve Life Sciences Inc earned $-1.25 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 0.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$49.5M

Achieve Life Sciences Inc generated -$49.5M in free cash flow in fiscal year 2025, representing cash available after capex.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

53M

YoY+53.5%

5Y CAGR+54.2%

Achieve Life Sciences Inc had 53M shares outstanding in fiscal year 2025. This represents an increase of 53.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$23.0M

YoY+0.6%

5Y CAGR+27.3%

10Y CAGR-0.9%

Achieve Life Sciences Inc invested $23.0M in research and development in fiscal year 2025. This represents an increase of 0.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$3K

5Y CAGR-29.3%

10Y CAGR-38.2%

Achieve Life Sciences Inc invested $3K in capex in fiscal year 2025, funding long-term assets and infrastructure.

ACHV Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$23.0M+0.6%	$22.8M+44.3%	$15.8M-47.4%	$30.1M+25.5%	$24.0M+248.2%	$6.9M
SG&A Expenses	$31.9M+96.1%	$16.3M+42.1%	$11.4M+6.7%	$10.7M+17.5%	$9.1M+16.0%	$7.9M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$819K-62.4%	$2.2M-23.6%	$2.9M+59.5%	$1.8M	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$54.6M-37.2%	-$39.8M-33.6%	-$29.8M+29.6%	-$42.4M-27.7%	-$33.2M-125.1%	-$14.7M
EPS (Diluted)	$-1.25-0.8%	$-1.24+17.3%	$-1.50+62.5%	$-4.00+2.0%	$-4.08+24.7%	$-5.42

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5.3M-20.7%	$6.7M-5.5%	$7.1M	N/A	$7.6M+48.8%	$5.1M+82.7%	$2.8M	N/A
SG&A Expenses	$9.4M+60.0%	$5.9M+1.0%	$5.8M	N/A	$4.9M+46.4%	$3.3M+4.2%	$3.2M	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$192K+0.5%	$191K+3.2%	$185K	N/A	$366K-54.5%	$804K-1.1%	$813K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$14.4M-13.5%	-$12.7M+0.8%	-$12.8M	N/A	-$12.5M-47.9%	-$8.5M-30.3%	-$6.5M	N/A
EPS (Diluted)	$-0.28+24.3%	$-0.370.0%	$-0.37	N/A	$-0.36-44.0%	$-0.25+3.8%	$-0.26	N/A

ACHV Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$38.6M+99.4%	$19.4M-35.4%	$30.0M-36.9%	$47.5M+17.9%	$40.3M
Current Assets	N/A	$36.5M+114.7%	$17.0M-37.9%	$27.3M-38.7%	$44.6M+20.6%	$37.0M
Cash & Equivalents	N/A	$12.8M-18.0%	$15.5M-37.2%	$24.8M-42.4%	$43.0M+20.0%	$35.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M
Total Liabilities	N/A	$17.7M-14.8%	$20.8M-3.9%	$21.7M+11.3%	$19.5M+546.5%	$3.0M
Current Liabilities	N/A	$6.7M-67.9%	$20.8M-3.6%	$21.6M+374.7%	$4.5M+55.0%	$2.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	$20.9M+1543.3%	-$1.4M-117.4%	$8.3M-70.4%	$28.0M-24.8%	$37.3M
Retained Earnings	N/A	-$205.6M-24.0%	-$165.8M-21.9%	-$135.9M-45.3%	-$93.6M-54.9%	-$60.4M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$52.0M-11.7%	$58.9M+115.4%	$27.4M-29.2%	$38.6M-19.4%	$47.9M-26.0%	$64.8M-7.5%	$70.0M+261.5%	$19.4M
Current Assets	$50.1M-12.0%	$56.9M+127.6%	$25.0M-31.4%	$36.5M-19.9%	$45.5M-27.2%	$62.5M-7.7%	$67.7M+298.7%	$17.0M
Cash & Equivalents	$31.9M-38.4%	$51.9M+298.5%	$13.0M+2.1%	$12.8M+33.6%	$9.5M-35.3%	$14.8M-77.8%	$66.4M+327.1%	$15.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M
Total Liabilities	$18.4M+6.7%	$17.3M+1.1%	$17.1M-3.7%	$17.7M+7.2%	$16.5M-26.5%	$22.5M+9.4%	$20.6M-1.2%	$20.8M
Current Liabilities	$9.7M+13.5%	$8.6M+20.2%	$7.1M+6.7%	$6.7M-0.5%	$6.7M-51.0%	$13.7M-33.4%	$20.6M-1.2%	$20.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$33.6M-19.3%	$41.7M+305.4%	$10.3M-50.8%	$20.9M-33.4%	$31.4M-25.8%	$42.3M-14.5%	$49.5M+3515.5%	-$1.4M
Retained Earnings	-$245.6M-6.2%	-$231.1M-5.8%	-$218.4M-6.2%	-$205.6M-6.4%	-$193.2M-6.9%	-$180.7M-4.9%	-$172.2M-3.9%	-$165.8M

ACHV Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$49.5M-66.2%	-$29.8M-21.6%	-$24.5M+34.8%	-$37.6M-27.6%	-$29.4M-118.5%	-$13.5M
Capital Expenditures	$3K	N/A	$21K	N/A	N/A	$17K
Free Cash Flow	-$49.5M	N/A	-$24.5M	N/A	N/A	-$13.5M
Investing Cash Flow	$6.1M+128.3%	-$21.6M-102661.9%	-$21K	N/A	N/A	-$17K
Financing Cash Flow	$51.5M+6.2%	$48.5M+217.6%	$15.3M-20.9%	$19.3M-47.2%	$36.6M+12.0%	$32.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$11.3M-24.9%	-$9.1M+18.2%	-$11.1M-20.7%	-$9.2M+11.4%	-$10.4M-110.8%	-$4.9M+6.9%	-$5.3M-21.2%	-$4.4M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$6K
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$4.4M
Investing Cash Flow	-$12.7M-288.8%	$6.7M-41.0%	$11.4M-3.1%	$11.7M-11.7%	$13.3M	N/A	N/A	-$6K
Financing Cash Flow	$4.0M	N/A	N/A	$682K+108.4%	-$8.1M-5202.0%	-$153K-100.3%	$56.1M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ACHV Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-190.6%	N/A	-510.1%-391.8pp	-118.2%-78.7pp	-39.5%
Return on Assets	N/A	-103.1%+50.8pp	-153.9%-12.6pp	-141.3%-71.5pp	-69.8%-33.2pp	-36.5%
Current Ratio	N/A	5.46+4.6	0.82-0.4	1.27-8.5	9.80-2.8	12.60
Debt-to-Equity	N/A	0.85+15.2	-14.38-17.0	2.61+1.9	0.69+0.6	0.08
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-43.0%-12.4pp	-30.5%+94.3pp	-124.8%	N/A	-39.9%-19.9pp	-20.0%-6.9pp	-13.1%	N/A
Return on Assets	-27.8%-6.2pp	-21.6%+25.3pp	-46.9%	N/A	-26.1%-13.1pp	-13.1%-3.8pp	-9.3%	N/A
Current Ratio	5.14-1.5	6.64+3.1	3.51-2.0	5.46-1.3	6.78+2.2	4.56+1.3	3.29+2.5	0.82
Debt-to-Equity	0.55+0.1	0.41-1.2	1.66+0.8	0.85+0.3	0.530.0	0.53+0.1	0.42+14.8	-14.38
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Nuvectis Pharma, Inc. NVCT

$202.7M

Milestone Pharmaceuticals MIST

$178.9M

Alpha Cognition ACOG

$134.8M

Coherus CHRS

$250.3M

Eledon Pharmaceuticals Inc ELDN

$234.4M

Frequently Asked Questions

Is Achieve Life Sciences Inc profitable?

No, Achieve Life Sciences Inc (ACHV) reported a net income of -$54.6M in fiscal year 2025.

What is Achieve Life Sciences Inc's free cash flow?

Achieve Life Sciences Inc (ACHV) generated -$49.5M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Achieve Life Sciences Inc's operating cash flow?

Achieve Life Sciences Inc (ACHV) generated -$49.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Achieve Life Sciences Inc's capital expenditures?

Achieve Life Sciences Inc (ACHV) invested $3K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Achieve Life Sciences Inc spend on research and development?

Achieve Life Sciences Inc (ACHV) invested $23.0M in research and development during fiscal year 2025.

How many shares does Achieve Life Sciences Inc have outstanding?

Achieve Life Sciences Inc (ACHV) had 53M shares outstanding as of fiscal year 2025.

Are Achieve Life Sciences Inc's earnings high quality?

Achieve Life Sciences Inc (ACHV) has an earnings quality ratio of 0.91x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.